Payment overview · 2025
General Payments
$268.70
13 reported records · 7 companies
Healthcare provider profile · identity verified
George G Boctor, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT LAUDERDALE, FL · NPI 1194925560
Verified facts
What the public records show
CMS Open Payments records show George G Boctor, MD received $268.70 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.68 | 20.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.52 | 20.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.20 | 17.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.68 | 12.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.67 | 11.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.04 | 9.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.91 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.70 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.52 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.20 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.67 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 904 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 363 | 105 |
| Lisinopril | Lisinopril | 319 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 79 |
| Carvedilol | Carvedilol | 259 | 72 |
| Omeprazole | Omeprazole | 252 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 244 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 73 |
| Alprazolam | Alprazolam | 210 | 52 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 197 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 71 |
| Losartan Potassium | Losartan Potassium | 177 | 52 |
| Metformin Hcl | Metformin Hcl | 169 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 45 |
| Trazodone Hcl | Trazodone Hcl | 124 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 69 |
| Azithromycin | Azithromycin | 101 | 78 |
| Eliquis | Apixaban | 99 | 27 |
| Simvastatin | Simvastatin | 97 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 25 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 92 | 92 |
| Glimepiride | Glimepiride | 89 | 25 |
| Finasteride | Finasteride | 85 | 31 |
| Lorazepam | Lorazepam | 85 | 16 |
| Sertraline Hcl | Sertraline Hcl | 83 | 24 |
| Gabapentin | Gabapentin | 82 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 15 |
| Bumetanide | Bumetanide | 71 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 28 |
| Prednisone | Prednisone | 71 | 61 |
| Allopurinol | Allopurinol | 61 | 21 |
| Potassium Chloride | Potassium Chloride | 61 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 58 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 18 |
| Atenolol | Atenolol | 57 | 15 |
| Entresto | Sacubitril/Valsartan | 57 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 15 |
| Temazepam | Temazepam | 56 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 15 |
| Furosemide | Furosemide | 50 | 19 |
| Valsartan | Valsartan | 48 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | 15 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 27 |
| Xarelto | Rivaroxaban | 39 | 12 |
| Famotidine | Famotidine | 38 | 20 |
| Clonazepam | Clonazepam | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.70 · 13 records | AstraZeneca Pharmaceuticals LP | BREZTRI, ELIQUIS, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error